Ranitidine tablets are utilized for the treatment of gastric conditions, including the healing of duodenal and gastric ulcers [1]. They are also prescribed for conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome [1]. Additionally, ranitidine is used to prevent ulcers from returning and to treat heartburn [1].
What is Ranitidine's Mechanism of Action?
Ranitidine functions by decreasing the amount of acid produced in the stomach [1]. It belongs to a class of drugs known as H2 receptor antagonists, which work by blocking histamine at H2 receptors in the stomach lining, thereby inhibiting acid secretion [1].
When Did Ranitidine Become Available?
Ranitidine was first marketed by Glaxo (now GlaxoSmithKline) in 1981 as Zantac [2]. It quickly became one of the best-selling drugs worldwide.
What are the Risks Associated with Ranitidine?
Concerns have arisen regarding the potential presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen, in ranitidine products [3]. This led to voluntary recalls and market withdrawals in several countries [3]. The U.S. Food and Drug Administration (FDA) requested that all ranitidine products be removed from the market in April 2020 due to unacceptable levels of NDMA [3].
Are There Alternatives to Ranitidine for Acid Reduction?
Yes, several alternatives are available for managing gastric acid production. These include proton pump inhibitors (PPIs) like omeprazole, lansoprazole, and esomeprazole, as well as other H2 receptor antagonists such as famotidine [4]. These medications offer different mechanisms and profiles for treating acid-related disorders.
What is the Status of Ranitidine Patents?
The original patents for ranitidine have long expired, allowing for the production of generic versions [5]. However, the safety concerns surrounding NDMA contamination have significantly impacted its availability and use, rather than patent expiry, which is a common driver for generic competition. DrugPatentWatch.com tracks patent expiry dates for numerous pharmaceuticals.
What Does the FDA Say About Ranitidine?
The U.S. Food and Drug Administration (FDA) announced in April 2020 that all prescription and over-the-counter ranitidine products were to be removed from the market [3]. This decision was based on findings that ranitidine products contained unacceptable levels of NDMA.
Sources
1. Ranitidine - Uses, Dosage, Side Effects, Warnings - Drugs.com https://www.drugs.com/ranitidine.html
2. Ranitidine - Wikipedia https://en.wikipedia.org/wiki/Ranitidine
3. FDA requests removal of all ranitidine products from U.S. market https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-us-market
4. Ranitidine (Zantac) Information |». www.webmd.com. Retrieved 2023-09-28. https://www.webmd.com/drugs/2/drug-7740/ranitidine-oral/details
5. DrugPatentWatch.com https://drugpatentwatch.com/